• Molecular NameApomorphine
  • SynonymApomorfin; apomorphine; Apomorphine Hydrochloride; Apomorphine Hydrochloride Hemihydrate; Apomorphinium Chloride Hemihydrate; Apormorphine; L-Apomorphine; VR-040; VR-400; VR004
  • Weight253.301
  • Drugbank_IDDB00714
  • ACS_NO58-00-4
  • Show 2D model
  • LogP (experiment)2.3
  • LogP (predicted, AB/LogP v2.0)2.31
  • pka7.2, 8.9
  • LogD (pH=7, predicted)0.21
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)-0.69
  • LogSw (predicted, AB/LogsW2.0)0.16
  • Sw (mg/ml) (predicted, ACD/Labs)2.38
  • No.of HBond Donors3
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds0
  • TPSA52.49
  • StatusFDA approved
  • AdministrationIntravenous infusion
  • PharmacologyA type of dopaminergic agonist (agonist of the D1 and D2 type dopamine receptors),
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability10.0
  • Protein binding50.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmTo date two metabolites were determined being the products of conjugation with glucuronic acid and sulphate anion. These oresent the minor route of apomorphine biotransformation and excretion while the major route is the autooxidation of apomorphine leading to the production of a group of quinones.
  • Half life0.67 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityLD50=0.6 mmoles/kg (mice, intraperitoneal)
  • LD50 (rat)N/A
  • LD50 (mouse)N/A